TABLE 2

Results of Association of HRCT Variables with PLC

VariableORPROC areaSeSpLR+LR−
Smooth lines2.26 (0.64–7.94)0.210.55 (0.46–0.64)0.90 (0.80–0.96)0.21 (0.07–0.42)1.13 (0.91–1.41)0.50 (0.18–1.43)
Nodular lines1.69 (0.44–6.52)0.450.53 (0.45–0.62)0.19 (0.11–0.31)0.88 (0.68–0.97)1.55 (0.48–4.98)0.92 (0.76–1.12)
Peribronchovascular thickening10.95 (3.33–36.0)<0.0010.76 (0.67–0.85)0.69 (0.56–0.79)0.83 (0.63–0.95)4.12 (1.66–10.2)0.38 (0.25–0.56)
Subpleural space0.44 (0.09–2.15)0.310.47 (0.39–0.54)0.06 (0.02–0.15)0.88 (0.68–0.97)0.48 (0.12–1.98)1.07 (0.91–1.26)
Satellite nodes0.65 (0.21–2.00)0.460.46 (0.36–0.56)0.18 (0.10–0.29)0.75 (0.53–0.90)0.72 (0.30–1.70)1.09 (0.85–1.41)
Enlarged lymph nodes4.65 (1.68–12.8)0.0030.68 (0.57–0.79)0.66 (0.53–0.77)0.71 (0.49–0.87)2.25 (1.18–4.3)0.48 (0.32–0.74)
Pleural effusion1.09 (0.27–4.40)0.910.50 (0.43–0.58)0.13 (0.06–0.24)0.88 (0.68–0.97)1.07 (0.32–3.64)0.99 (0.83–1.18)
Enlarged pulmonary veins0.32 (0.07–1.39)0.130.45 (0.37–0.53)0.06 (0.02–0.15)0.83 (0.63–0.95)0.36 (0.10–1.32)1.13 (0.93–1.36)
  • Se = sensitivity; Sp = specificity; LR+ = positive likelihood ratio; LR− = negative likelihood ratio.

  • Data in parentheses are 95%CI. P < 0.003 was considered statistically significant to account for multiple testing.